Drug Therapy, Combination

4 trials

Conditions

Cancer of ovary, fallopian tubes and / or peritoneum.Coronavirus disease 2019 (COVID-19) COVID-19, pneumoniaNon-surgical malignant esophagus tumors.Pancreatic cancer locally advanced unresectable or metastatic

Phase 2

h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin.

Active, not recruitingRPCEC00000014

Center of Molecular Immunology(CIM)Non-surgical malignant esophagus tumors.

Start: 2005-12-14Target: 68Updated: 2026-03-30

Phase II trial of combination therapy with favipiravir and corticosteroids for COVID-19

Active, not recruitingJPRN-jRCTs041200025

Yuichiro ShindoCoronavirus disease 2019 (COVID-19) COVID-19, pneumonia

Start: 2020-07-01Target: 69Updated: 2025-07-18

Phase 3

CENTAURO-4 Study

Active, not recruitingRPCEC00000246

Center for Genetic Engineering and Biotechnology (CIGB), in Havana.Cancer of ovary, fallopian tubes and / or peritoneum.

Start: 2017-05-02Target: 40Updated: 2026-03-30

Phase 4

Nimotuzumab-pancreatic cancer-adults-Phase IV.

RecruitingRPCEC00000245

Center of Molecular ImmunologyPancreatic cancer locally advanced unresectable or metastatic

Start: 2017-05-15Updated: 2026-03-30

Related Papers

Nimotuzumab Concurrent with Gemcitabine as First‐Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma

BioMed Research International2023-01-012 citations

Phase II Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure